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Summary. Background: Activated factor X (FXa) is a vitamin
K-dependent serine protease that plays a pivotal role in blood
coagulation by converting prothrombin to thrombin. There
are no reports of humans with complete deficiency of FX,
and knockout of murine F10 is embryonic or perinatal
lethal. Objective: We sought to generate a viable mousemodel
of FX deficiency. Methods: We used a socket-targeting con-
struct to generateF10-knockoutmice by eliminatingF10 exon 8
(knockout allele termed F10tm1Ccmt, abbreviated as ); wild-
type +), and a plug-targeting construct to generate mice
expressing a FX variant with normal antigen levels but low
levels of FX activity [4–9% normal in humans carrying the
defect, Pro343 fi Ser, termed FX Friuli (mutant allele termed
F10tm2Ccmt, abbreviated as F)]. Results: F10 knockout mice
exhibited embryonic or perinatal lethality. In contrast, homo-
zygous Friuli mice [F10 (F/F)] had FX activity levels of5.5%
(sufficient to rescue both embryonic and perinatal lethality), but
developed age-dependent iron deposition and cardiac fibrosis.
Interestingly, F10 ()/F) mice with FX activity levels of 1–3%
also showed complete rescue of lethality. Further study of this
model provides evidence supporting a role of maternal FX
transfer in the embryonic survival. Conclusions: We demon-
strate that, while complete absence of FX is incompatible with
murine survival, minimal FX activity as low as 1–3% is
sufficient to rescue the lethal phenotype. This viable low-FX
mouse model will facilitate the development of FX-directed
therapies as well as investigation of the FX role in embryonic
development.
Keywords: coagulation, development, factor X, mouse model.
Introduction
The hemostatic process is a complex, highly regulated and
dynamic sequence of events that ultimately results in the
localized formation of a stable clot in response to vascular
damage [1]. Activated coagulation factor X (FXa; a vitamin K-
dependent, two-chain plasma serine protease) catalyzes the
conversion of prothrombin to thrombin and occupies a pivotal
role in the coagulation cascade. Under physiological condi-
tions, cleavage of FX to form FXa is initiated by the FVIIa/
tissue factor (TF) complex andmaintained by the FIXa/FVIIIa
complex.
Several lines of evidence suggest that FX/FXa may have
functions other than hemostasis, such as promoting cytokine
release from endothelial cells and initiating signaling via
protease activated receptors (PARs) [2,3]. Interestingly, no
humans with deletion of both F10 genes have been reported.
Instead, all of the described mutations are either missense
mutations or compound heterozygotes with a deletion or stop
codon on one allele and a missense mutation on the other,
suggesting that complete deficiency of FX is incompatible with
life (http://www.hgmd.cf.ac.uk/ac/index.php) [4]. Similar find-
ings have been described in mice, in which targeted disruption
of theF10 gene is associated with loss of50%of homozygous
affected animals in utero, and loss of the remaining affected
mice as a result of bleeding complications within a few days of
birth [5].
In this study, we sought to develop a viable mouse model
of FX deficiency and to determine whether very low levels of
FX activity could rescue the embryonic and perinatal lethality.
We used a plug and socket targeting strategy; the socket
targeting construct eliminated exon 8 and its 3¢ flanking
sequence following homologous recombination, to give rise to
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F10-knockout mice (knockout allele F10tm1Ccmt abbreviated as
–; wild-type F10 allele abbreviated as +) exhibiting embry-
onic and perinatal lethality [6]. We chose exon 8 as almost 50%
of the reported F10mutations are located within this exon. We
used a second (plug) targeting construct to reconstitute the F10
gene with a variant exon 8 containing a Pro343 fi Ser
substitution (FX Friuli, allele F10tm2Ccmt abbreviated as F),
which, in humans homozygous, results in FX activity levels of
4–9% and normal antigen levels [7]. Homozygous FX Friuli
mice [F10 (F/F)], with expression directed by the endogenous
F10 promoter, yielded FX activity levels of 5.5%, and complete
rescue of embryonic and perinatal lethality of FX deficiency.
We used this genetic approach to further define the role of FX
in embryonic survival and generated mice with the F10 ()/F)
genotype. We demonstrate that FX activity levels of 1–3%
were sufficient for complete rescue of embryonic and perinatal
lethality, and provided evidence for a contribution of maternal
transfer of FX activity to embryonic survival. These mice can
be used in studies of novel therapies for FX deficiency as well as
probing the role of FX in processes such as sepsis and
metastasis.
Methods
Isolation of murine F10 genomic DNA
Designed from the exon 8 sequence of the murine F10 gene, a
350-bp fragment from 129/SvJ mouse genomic DNA (Strata-
gene, La Jolla, CA, USA) was amplified using polymerase
chain reaction (PCR) and sequenced. This was used as a probe
to screen a bacterial artificial chromosome (BAC) library
derived from HindIII, partially digested embryonic stem (ES)
129/SvJDNA (Genome Systems, St Louis,MO,USA). A 7-kb
NheI-digested fragment was isolated from a positive BAC clone
containing exons 7 and 8, the intervening intron, and the
flanking region downstream of exon 8. This fragment also was
used to design and construct the F10 socket-targeting vector.
Construction of the F10 socket- and plug-targeting vectors
Engineered in the pPD20 plasmid vector (provided by Dr
Randy Thresher, UNC-Chapel Hill, USA), the F10 socket-
targeting construct consists of 5¢ (2.8-kb including intron 6,
exon 7, and part of intron 7 of the murine F10 gene) and 3¢
[1.6-kb containing the sequence downstream of the putative
polyadenylation signal (ATTAAA) and the overlapping ter-
mination codon (TAA) of theF10 gene] homologous sequences
flanking a functional neomycin (Neo) gene and a partially
deleted, non-functional HPRT minigene (DHPRT) (Fig. 1A)
[6]. The F10 plug-targeting construct cloned in pBY9 plasmid
has the identical 5¢arm as the F10 socket-targeting vector; its
3¢arm contains a 1.4-kb overlapping HPRT sequence with the
pPD20 plasmid (Fig. 1E). In the plug-targeting construct, exon
8 has been modified by site-directed mutagenesis at the codon
for amino acid 343 (in mouse FX protein) to generate the
Pro343 fi Ser (FX Friuli) mutation (CCC fi TCC) [7].
Electroporation, selection, analysis of ES cell clones and DNA
extraction
HPRT-deficient murine ES cells (E14TG2a) were grown as
described [8] and electroporatedwith 100 lg of SacII-linearized
F10 socket-targeting vector and G418-selected. For the F10
plug-targeting construct, HPRT-deficient murine ES cells
heterozygous for deletion of exon 8 (from the original targeting
event)were electroporated as above and selected basedonG418
sensitivity and growth in HATmedium [9]. ES cell clone DNA
as well as liver DNA from neonates was isolated using the Easy
DNA Kit (Invitrogen, Carlsbad, CA, USA). All ES cell clones
were identified by PCR and/or Southern blot. For adult mice,
genomic DNA was extracted from blood samples using the
QIAamp DNA BloodMini Kit (Qiagen, Valencia, CA, USA).
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Fig. 1. Plug and socket targeting strategy for generation of F10 knockout
and Friuli mice. (A) Socket targeting construct consists of 2.8 kb 5¢tar-
geting arm and 1.6 kb 3¢ targeting arm derived from 3¢untranslated region
of murine F10 gene. The targeting arms flank a functionalNeo gene and a
partially deletedHPRT gene (DHPRT). (B) The 3¢ end of the murine F10
locus. (C) After homologous recombination between the socket construct
(A) and the murine F10 locus (B), exon 8 is replaced with theNeo gene and
partial HPRT gene. (D) F10 knockout locus showing deleted exon 8
replaced by Neo and partial HPRT. (E) F10 plug targeting construct
contains variant exon 8 with Friuli mutation (*) and the missing 5¢ portion
of theHPRT gene, flanked by 5¢ and 3¢ targeting arms. (F) Reconstitution
of the HPRT gene after homologous recombination allows selection of
correctly targeted clones on HAT medium. Arrows indicate primer pairs
used for polymerase chain reaction identification. The darkened bar shows
the location of the probe for Southern blot.
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Generation of F10 ()/)), F10 (F/F), and F10 ()/F) mice
The production of all chimeric mice was performed by the
Transgenic & Chimeric Mouse Facility of the University of
Pennsylvania (USA). Correctly targeted F10 (+/)) and F10
(+/F) murine ES cell clones were expanded, micro-injected
into C57BL/6 blastocysts, and implanted into the uterine
horns of pseudo-pregnantmice. The chimericmalesweremated
with wild-type C57BL/6 females to generate heterozygous F10
(+/)) or F10 (+/F) offspring, which were intercrossed to
obtain homozygous F10 ()/)) or F10 (F/F) mice, respectively.
F10 ()/F) mice were generated by crossing homozygous F10
(F/F) females with heterozygous F10 (+/)) males.
Reverse transcription-polymerase chain reaction and Northern
blotting of total RNA isolated from liver tissues
Total RNA was isolated from liver of F10 (+/+) and F10
()/)) newborn mice, using TRIzol reagent (Invitrogen),
reverse transcribed into first-strand cDNA using oligo(dT)
primers (Invitrogen) and PCR-amplified for exons 1–6 and
exon 8. For Northern blot analysis, total RNA (20 lg) was
isolated from liver of neonates, and hybridized with a F10
cDNA fragment corresponding to exons 1–6. A b-actin
cDNA probe was used as a control. Band intensity was
determined by densitometry.
Western blot analysis on plasma samples and protein samples
isolated from liver tissues
Plasma samples or liverprotein extractswereobtained fromF10
(+/+), F10 (+/)), and F10 ()/)) neonates and from F10 (+/
+), F10 (+/)), and F10 (F/F) adult mice and analyzed by
Western blotting [10]. A horseradish-peroxidase (HRP) conju-
gated rabbit antihumanFXpolyclonal antibody (1:300dilution;
Cedarlane, ON, Canada) or an affinity-purified sheep antihu-
man FX polyclonal antibody (1:250 dilution; Cedarlane),
followed by anHRP-conjugated rabbit antisheep immunoglob-
ulin (1:1000 dilution; Dako, Carpinteria, CA, USA) were used.
Activated partial thromboplastin time and prothrombin time
FX assays
Citrated plasma collected from neonates and adult mice (4–
6 weeks old) was used to measure FX coagulation activities by
activated partial thromboplastin time (aPTT) and prothrombin
time (PT) assays (diluted 1:40 for aPTT, 1:80 for PT), as
previously described [11]. Clotting times were converted to
percent normal FX activity using a pooled normal mouse
plasma standard curve.
Histologic analysis of FX-deficient mice
Adult mice were sacrificed by CO2 inhalation; organs were
harvested and fixed in 10% formalin overnight at 4 C. Tissues
were embedded in paraffin, sectioned (5 lm per section), and
stained with hematoxylin and eosin, Prussian blue, orMassons
Trichrome stain.
Results
Construction of mice with targeted disruption of exon 8
With the expectation that a deletion ofmurine F10would result
in lethality, which would then require rescue to produce a
viable FX-deficient mouse model, we chose to use the plug-
and-socket targeting strategy originally described by Detloff
et al. [6]. As well as being different from the previously
described FXdeficiencymousemodel [5], this approach has the
advantage that it allowed us to inactivate and then replace the
targeted region with another sequence of interest, which would
then express a low-activity FX variant under the control of the
endogenous promoter and its regulatory sequences. Using a
targeting construct (socket) designed to delete exon 8 (Fig. 1A),
we electroporated HPRT-deficient murine ES cells and iden-
tified correctly targeted ES clones (8/192 screened, 4%) that
were expanded and micro-injected into C57BL/6 blastocysts.
The resulting chimeric males were mated with wild-type
C57BL/6 females. Subsequently, heterozygous F10 (+/)) mice
were intercrossed to obtain homozygous F10 ()/)) offspring.
Characterization of FX-deficient ()/)) neonates
DNA analysis of the full-term offspring (n = 213) resulting
from mating of heterozygous F10 (+/)) mice showed that F10
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Fig. 2. Characterization of F10 ()/)) mice. (A) Genotype distribution
among offspring of heterozygous F10 (+/)) intercross. F10 ()/)) mice are
under-represented. n = number of animals; P values are compared to
normalMendelian distribution (25%, 50%, 25%) using a chi-squared test.
(B) Reverse transcription-polymerase chain reaction analysis for F10
transcripts on RNA isolated from newborn mouse liver. M, molecular
weight marker. Odd numbered lanes, F10 (+/+) mice; even numbered
lanes,F10 ()/)) mice; lanes 1–2, exons 1–6; lanes 3–4, exons 5–7; lanes 5–6,
exon 8; lanes 7–8, b-actin cDNA. (C) Western blot analysis on mouse
plasma from F10 (+/+), (+/)), and ()/)) newborn mice, or from F10
(+/+) or F10 (+/)) adults [note that F10 ()/)) mice do not survive to
adulthood]. The 55 kD signal from mouse factor X is readily detected in
F10 (+/+) and F10 (+/)) animals but not in F10 ()/)) newborn mice.
(D) Coagulation times (s) on newborn mice. Times are averages for 6–31
mice per genotype. Asterisk denotes clotting time >200 s.
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()/)) newborns (12%) were under-represented (P < 0.001;
Fig. 2A), confirming the occurrence of partial embryonic
lethality and exhibiting similar pathology and survival (data
not shown) as previously described [5]. Analysis of F10-null
embryos showed that as early as embryonic day 11.5, F10 ()/))
embryos accounted for only 14% of progeny (n = 104,
P < 0.05), indicating that most of the F10 ()/)) embryo loss
had occurred by mid-gestation.
Further analysis of the F10 ()/)) mice showed absence of a
correctly sized F10 transcript by Northern blot on total liver
RNA, although a very faint, larger than wild-type F10
transcript was observed (data not shown), most likely contain-
ing part of the Neo-DHPRT cassette. More sensitive method-
ology (reverse transcription-PCR) revealed a markedly
reduced, but nonetheless detectable, signal for exons 1–6
(Fig. 2B, lane 2) and, as expected, absence of signal for exon 8
(Fig. 2B, lane 6). The faint, larger than wild-type F10
transcript, most likely accounted for the amplification of exons
1–6 as well as 5–7 (Fig. 2B, lane 4). Corroborating these results,
F10 ()/)) mice did not have any detectable circulating FX
antigen byWestern blot [in contrast to their wild-type and F10
(+/)) littermates; Fig. 2C] and, as expected, exhibited
prolonged clotting times (Fig. 2D).
Knock-in of F10 Friuli and characterization of mice
homozygous for variant FX
Clearly, the embryonic and perinatal mortality of the F10 ()/))
mice limit their utility for studies of FX therapeutics. We
therefore sought to rescue the mortality by restoring a low level
of FX expression under the control of the endogenous F10
promoter. We selected an exon 8 mutation from the human
mutation database that is associated with reduced but not
absent FX activity, FX Friuli. This missense mutation
(Pro343 fi Ser) in the catalytic domain exhibits normal antigen
but reduced activity levels of 4–9% [7]. Given the extensive
sequence and functional conservation in the catalytic domain
of FX across species, we were able to generate a plug-targeting
construct containing the identical mouse F10 gene mutation,
expected to have a similar functional effect. We carried out a
retargeting experiment on the original, targeted murine ES cells
to generate mice expressing the FX Friuli mutation. The use of
two selectable markers results in a high rate of correctly
retargeted ES cells; 9/48 clones examined (19%), in contrast to
8/192 (4%) from the original targeting event, were correctly
targeted as assessed by PCR and Southern blot analyses. The
results of the F1 intercross of F10 (+/F) mice are summarized
in Fig. 3A [compared to results of the F1 intercross of F10 (+/
)) mice in Fig. 2A]. These show that F10 (F/F) mice are born
at the expected frequency based on Mendelian inheritance,
confirming that the Friuli variant rescues embryonic lethality.
Secondly, perinatal lethality is also rescued; indeed, survival is
comparable to that of littermates with the F10 (+/F) genotype
(80% at 18 months). Determination of FX antigen and activity
levels in the F10 (F/F) mice reveals normal antigen levels
as judged by Western blot (Fig. 3B), and intrinsic and
extrinsic activity of 5.5 ± 1.8% and 5.5 ± 1.9%, respec-
tively (Fig. 3C). As expected, F10 (+/F) mice exhibited
approximately 50% intrinsic/extrinsic activity (Fig. 3C). Thus,
the murine model of FX Friuli is similar to the human
mutation in terms of phenotype, activity, and antigen levels.
Furthermore, the reproductive fitness of F10 (F/F) mice is
indistinguishable from that of the wild-type mice; female F10
(F/F) mice have litter sizes similar to those of wild-type females
(data not shown).
Survival of mice with very low FX levels [F10 ()/F)]
The homozygous Friuli mice [F10 (F/F)], although useful as
a model for FX deficiency, nevertheless failed to define a
lower limit of FX activity required for survival. To generate
and characterize mice with even lower levels of FX, we
crossed the F10 (F/F) females with F10 (+/)) males to
generate F10 ()/F) offspring [F10 (F/F) females rather than
F10 (+/)) females were used in this mating scheme to
confirm the reproductive competence of these mice]. Such
Parental F10
genotype
Total
offspring
F10 genotype
P value+/+n (%) n (%) n (%)
+/- or +/F
+/F cross +/F 298
F10 genotype
+/+ +/+ F/F F/F F/F F/F
1:201:51:201:51:201:5
100
80
60
aPTT
PT
0
Ac
tiv
ity
 (%
 w
ild
 ty
pe
)
F10 (+/F) F10 (F/F)
40
20
81 (27) 153 (51) 64 (22) > 0.2
-/- or +/F
A
B
C
Fig. 3. Characterization of factor X Friuli [F10 (F/F)] mice. (A) Genotype
of live offspring of heterozygous crosses. Mice homozygous for the Friuli
knock-in are born at the expected frequency [22%, compared to F10 ()/))
mice born at 12% from a F10 (+/)) intercross]. n = number of animals;
P values are compared to normal Mendelian distribution (25%, 50%,
25%) using a chi-squared test. (B) Western blot analysis of plasma from
adult mice [F10 (+/+) or F10 (F/F)] at two dilutions (as indicated).
Antigen levels are similar for both genotypes. (C) Coagulation activity of
adult mice (n = 4 per genotype) from F10 (+/F) intercross (expressed in
% wild-type).
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matings showed the expected genotypic distribution (Table 1,
P > 0.2). Intrinsic and extrinsic FX activity in the F10 ()/F)
mice was 1.1 ± 0.1% and 2.9 ± 0.2%, respectively
(Table 1). Postnatal survival of the F10 ()/F) is normal,
clearly demonstrating that FX activity levels as low as 1–3%
are adequate to rescue embryonic and perinatal mortality in
F10 ()/)) mice. One hundred percent of F10 ()/F) mice
survived for the first postnatal month and 80% have
survived for at least 15 months.
Histologic analysis of FX-deficient mice
The F10 (F/F) and F10 (–/F) mice demonstrated relatively
normal survival through the postnatal period. However, a
previous report documents that both low TF (1%) and low
FVII (1%) mice exhibit cardiac fibrosis shown to have
resulted from recurrent episodes of hemorrhage into the
myocardium from cardiac vessels [12]. We therefore examined
cardiac tissue from 10-month-oldF10 (F/F)mice, and observed
similar findings – iron deposition in the myocardium (Prussian
blue staining) and co-localized fibrosis (Massons Trichrome
staining; Fig. 4E–L) – in contrast to age-matched littermates
(Fig. 4A–D). These findings are consistent with the observa-
tions made by Pawlinski et al. [12] in low TF and low FVII
mice. Examination of F10 (F/F) mice at an earlier time point
(three months of age) failed to disclose evidence of iron
deposition or cardiac fibrosis (data not shown). These results
suggest that both age and genotype of the mice are important
contributors to development of cardiac fibrosis in these FX-
deficient mice.
Role of maternal FX in embryonic survival
Viable and reproductively fit, the Friuli mice [F10 ()/F)]
provided an opportunity to assess the role of maternal FX
levels in embryonic survival, as it enabled a comparison of F10
()/F) intercross offspring (maternal FX activity levels1–3%,
antigen levels 50%) with F10 (+/)) intercross offspring
(maternal FX antigen and activity levels 50%). The data
(Table 2) demonstrate that there is a statistically significant
decrease in F10 ()/)) offspring (2% of total progeny) in the
F10 ()/F) intercross compared to F10 ()/)) offspring (12% of
total progeny) in the F10 (+/)) intercross (P = 0.0045, see
Fig. 2A), suggesting that maternal transfer of FX occurs
during development and that low FX activity levels in the
maternal circulation result in reduced survival of F10 ()/))
embryos.
Discussion
Severe FX deficiency has a low incidence, of the order of one
case per 500 000, and complete absence of FX has never been
reported. A recently compiled database (http://www.
hgmd.cf.ac.uk/ac/index.php) [4] confirms this finding. These
data in humans are consistent with the data presented here;
mice with homozygous deletion of the F10 gene show a
reduction in numbers occurring as early asE11.5 and are thus
born in reduced numbers (approximately 50% of expected
numbers), exhibiting 100% perinatal mortality.
Because of an interest in developing new approaches for the
treatment of bleeding disorders [13–16], and to analyze the
potential role of FX in pathophysiological processes such as
sepsis and metastasis [17,18], we wished to develop a viable
murine model of severe FX deficiency. The only extant model
[15] requires in utero transplantation of wild-type fetal liver, a
cumbersome manipulation and not transmissible from one
generation to the next. The plug-and-socket methodology
Table 1 Characterization of F10 knockout/Friuli [F10 ()/F)] heterozygotes
Parental F10 genotype Total offspring
F10 genotype
P value *+/F n (%) )/F n (%)
F/F ($) cross +/) (#) 97 52 (54%) 45 (46%) >0.2
aPTT (Sec [%]) Normal F10 (+/+) range: 35.5 ± 1.6 (100%) 74.1 ± 1.3 (1.1%) n = 4
PT (Sec [%]) Normal F10 (+/+) range: 34.5 ± 2.1 (100%) 97.3 ± 2 (2.9%) n = 4
*Values are compared to normal Mendelian distribution (25%, 50%, 25%) using chi-squared test. aPTT, activated partial thromboplastin time;
PT, prothrombin time.
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Fig. 4. Histology of heart tissue fromwild-type and F10-Friuli [F10 (F/F)]
mice sacrificed at 10 months of age. Prussian blue and Massons
Trichrome stains on F10 (+/+)mice (A)–(D) and F10 (F/F)mice (E)–(L).
Prussian blue stain is positive for iron deposition in F10 (F/F) mice but not
in wild-type mice. Similarly, Massons Trichrome stain is positive for
fibrosis in F10 (F/F) mice but not in wild-type mice. (A), (C), (E), (G)
Magnification 10·; (B), (D), (F), (H) magnification 40·; (I), (J), (K), (L)
magnification 100·.
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utilized here facilitates repeated modification of a specific locus
as well as expression of the gene of interest under the control of
the endogenous promoter, thus preserving the temporal and
spatial patterns of expression during embryonic development.
Exon 8 was chosen because we wanted to target a region of the
F10 gene that encodes variants with a range of activities, as
nearly half of the reported patients with FX deficiency have
mutations in exon 8.
We restored FX expression using a FX variant with
extremely low activity and normal antigen levels, FX Friuli
[7]. Based on extensive conservation of the catalytic domain
between species, we hypothesized that (i) the mutant murine
protein would have activity levels similar to that of the
human protein, and (ii) these levels would be adequate to
rescue both embryonic and postnatal lethality. Both of our
hypotheses proved to be correct; the FX Friuli [F10 (F/F)]
mice have normal antigen levels, and activity levels quite
similar to those of homozygous affected humans (5.5% in
mice, 4–9% in humans), and these levels are adequate to
rescue both embryonic and postnatal lethality. From F10
()/F) mice, we also established that FX activity levels of
only 1–3%, and/or antigen levels of 50%, are adequate
for such rescue. At the molecular level, the murine Friuli
mutation in exon 8 most likely causes a similar structural
perturbation in the catalytic domain as has been proposed
for its human counterpart [19], thus affecting its catalytic
potential. Clearly, further studies will help to define the role
of this mutation in the mechanistic and molecular interac-
tions of FX within the coagulation cascade.
The Friuli mice, viable but with low circulating levels of
FX, can be used to address the role of maternal clotting
factor levels on embryonic survival, a point of uncertainty in
the literature. Although our data are indirect, a comparison
of two intercrosses [F10 ()/F) intercross and F10 (+/))
intercross; Table 2] strongly suggests that embryonic survival
of FX-deficient mice is improved by the presence of
biologically active FX in the mother. For example, F10 ()/
F) and F10 (+/)) mothers had distinct levels of FX activity
(1–3% and 50%, respectively) but similar antigen levels
(50%), suggesting that presence of maternal FX antigen is
not sufficient to improve embryonic survival. Thus, the
partial penetrance of the embryonic lethality in F10 null
embryos is, at least partly, a function of maternal transfer of
FX. A probable biological significance of maternal transfer
of FX (and other coagulation factors in general) may be
the prolongation of survival of embryos with FX or other
coagulation deficiencies that would otherwise succumb.
Moreover, although relative embryonic survival of F10
knockout mice [F10 ()/))] is directly dependent on the
specific genotype of the mother (with respect to FX activity
levels), our data suggest that embryonic and postnatal
survival of F10 ()/F) mice is independent of the mothers
genotype. This is clearly shown in both the F10 (F/F) · F10
(+/)) cross and the F10 ()/F) intercross (Tables 1 and 2,
respectively), where F10 ()F) mice were born in numbers
that establish lack of embryonic lethality.
In summary, we have shown that both embryonic and
postnatal lethality of FX deficiency can be rescued by
knock-in of a variant FX molecule with reduced activity
and normal antigen levels (FX Friuli), and that this mouse
model accurately models the mild human bleeding diathesis.
Moreover, F10 ()/F) mice had FX antigen levels of 50%
and activity levels of 1–3%, and also survived the embryonic
and postnatal periods. Our strategy has made it possible to
separate the roles of antigen and activity in embryonic
development. It represents a genetic approach to assessing
the role of maternal transfer of FX biological activity in
embryonic survival, and demonstrates that mere presence of
FX antigen is not sufficient. Additionally, these mice provide
a viable model for those interested in studying novel
therapies for FX deficiency, for investigation of the causes
of embryonic lethality in FX-deficient mice and for the role
of FX in biological processes such as sepsis and metastasis.
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